EOLS Quote, Financials, Valuation and Earnings

Iovance Biotherapeutics, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of -135.28%. Evolus, Inc.'s return on equity of -5666.82% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Evolus, Inc. has a consensus price target of $18.50, signalling upside risk potential of 171.66%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 275%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Evolus, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Evolus, Inc..

Evolus, Inc. has a beta of 0.870, which suggesting that the stock is 12.986% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Evolus, Inc.'s net income of -$15.7M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 1.53x versus 2.91x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

KalVista Pharmaceuticals, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of -361.39%. Evolus, Inc.'s return on equity of -5666.82% beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.

Evolus, Inc. has a consensus price target of $18.50, signalling upside risk potential of 171.66%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 89.02%. Given that Evolus, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Evolus, Inc. is more attractive than KalVista Pharmaceuticals, Inc..

Evolus, Inc. has a beta of 0.870, which suggesting that the stock is 12.986% less volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. Evolus, Inc.'s net income of -$15.7M is higher than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 1.53x versus 56.89x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of 15.59%. Evolus, Inc.'s return on equity of -5666.82% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

Evolus, Inc. has a consensus price target of $18.50, signalling upside risk potential of 171.66%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 17.46%. Given that Evolus, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Evolus, Inc. is more attractive than Travere Therapeutics, Inc..

Evolus, Inc. has a beta of 0.870, which suggesting that the stock is 12.986% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Evolus, Inc.'s net income of -$15.7M is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 1.53x versus 7.36x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenetic Biosciences, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of -49.65%. Evolus, Inc.'s return on equity of -5666.82% beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.

Evolus, Inc. has a consensus price target of $18.50, signalling upside risk potential of 171.66%. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1474.8%. Given that Xenetic Biosciences, Inc. has higher upside potential than Evolus, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Evolus, Inc..

Evolus, Inc. has a beta of 0.870, which suggesting that the stock is 12.986% less volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than Xenetic Biosciences, Inc. quarterly revenues of $1M. Evolus, Inc.'s net income of -$15.7M is lower than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 1.53x versus 1.37x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.